This limitation can be addressed through the administration of Exendin-4 via intraperitoneal injection
Jacob S, Hery M, Protois JC, Rossert J, Stengel B
Early trials suggest Retatrutide may be more potent, but its still under study
Pharma Lab Global is a reputable source of peptides worldwide
The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
Not surprisingly, the clinical success of these treatments has reached a plateau